Maintenance Infliximab for Immune-Mediated Inflammatory Diseases, Omega-3 Fatty Acids for Depression, DOACs and Atrial Fibrillation, and more
Editor's Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the December 21, 2021 issue. (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - December 21, 2021 Category: General Medicine Authors: JAMA Network Source Type: podcasts
TWiV 814: COVID-19 clinical update #83 with Dr. Daniel Griffin
In COVID-19 clinical update #83, Daniel Griffin discusses upcoming FDA discussions on vaccines, strategies to prevent transmission at youth camps, outbreaks at summer camps, impact of vaccination on transmission, AZD7442 request for EUA filed, EUA issued for home antigen test, phase 3 data on AZD1222 vaccine, 6 month effectiveness of Pfizer/BioNTech vaccine, estimates of durability of immunity against reinfection, Molnupiravir interim results, optimal time for monoclonal antibody infusion, IVIG plus Infliximab for MIS-C, and effect of vaccination on long COVID. Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free)...
Source: This Week in Virology - MP3 Edition - October 9, 2021 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Crohn's Disease Patients
A study in the March 2015 issue of CGH finds that withdrawal of immunomodulators after at least 6 months of co-treatment with infliximab does not reduce the trough levels of infliximab in patients with Crohn's disease. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - April 2, 2015 Category: Gastroenterology Authors: AGA Source Type: podcasts
Restarting Infliximab in IBD Patients with Prior Loss of Response
An article and accompanying editorial in the September issue of CGH discuss reinitiating infliximab therapy for inflammatory bowel disease patients after a period of discontinuation. Dr. Kuemmerle speaks w/ editorial co-author Dr. Maria T. Abreu. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - September 8, 2014 Category: Gastroenterology Authors: CGH Source Type: podcasts
Cost-Effective Treatment for Crohn's Disease Patients Who Lose Responsiveness to Infliximab
A study in the June issue of CGH looks at whether a test-based or empiric dose-escalation strategy is more cost-effective for treating Crohn's disease patients who have stopped responding to Infliximab. Dr. Kuemmerle speaks to Dr. Fernando S. Velayos. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - June 4, 2013 Category: Gastroenterology Authors: AGA Source Type: podcasts
